Innate Pharma ADR (NASDAQ:IPHA) traded at $2.12 at last check on current trade day and made an upward move of 9.28% on its previous day’s price.
Looking at the stock we see that its previous close was $1.94 and the beta (5Y monthly) reads 0.788 with the day’s price range being $2.04 – $2.35. In terms of its 52-week price range, IPHA has a high of $3.51 and a low of $1.29. The company’s stock has gained about 26.95% over that past 30 days.
Innate Pharma ADR has a market cap of $177.68 million and is expected to release its quarterly earnings report in March.
According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 54.96M, or -10.83% down from figures reported last year.
On the other hand, looking at the outlook for the IPHA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of Hold.
Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Innate Pharma ADR (IPHA) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 14.02% off its SMA20 and 12.38% from its 50-day simple moving average. The RSI (14) is pointing at 63.53 while the volatility over the past week is 2.88% and jumps to 5.57% over the past one month. The beta value is 0.20, while the average true range (ATR) is currently pointing at 0.15.
Coming back to Innate Pharma ADR (NASDAQ:IPHA), we note that the average 3-month trading volume was 509.81K, while that of the preceding 10-day period stands at 25530.0. Current shares outstanding are 80.95 million.
